Feb. 20 at 8:43 PM
$ZBIO $7.62 +1.19. DAC
$7.55 (2.4.25). EXIT
$14.00.
UPDATE: Zenas Biopharma +20% making a nice move today after disclosing that its CEO bought 25,000 shares at
$6.54-6.91 on Feb 18 ; Compnay was a recent IPO, making its debut in Sept 2024, underwriters with Morgan Stanley, Jefferies, Citigroup, and Guggenheim acting as joint book-running managers. However, after pricing at
$17 and opening at
$18.35, the stock has pulled back quite a bit since mid-November.
Investors are seeing this purchase as a positive.
OVERVIEW:
2024 accomplishments, outlined its key business objectives for 2025 and announced preliminary unaudited cash balance as of year-end 2024 (7.66)
^ Advancing Phase 2 and Phase 3 trials of obexelimab, a unique CD-19 x Fc?RIIb inhibitor of B cell function.
^ Topline results from Phase 2 Trial in Relapsing Multiple Sclerosis (MoonStone) expected in third quarter 2025.
^Topline results from pivotal Phase 3 Trial in Immunoglobulin G4-Related Disease ) expected year-end 2025.
